| Impact of Excision Margins on Survival and Recurrence Rate in Patients With Thick Melanoma (>2mm) (NCT02088762) | Insel Gruppe AG, University Hospital Bern | 1997-01-01 |
| Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083) (NCT00749684) | Merck Sharp & Dohme LLC | 1996-12-01 |
| Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease (NCT00001503) | National Cancer Institute (NCI) | 1996-09-19 |
| A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant (NCT00001439) | National Cancer Institute (NCI) | 1995-06-01 |
| Retinoblastoma Biomarker Study (NCT00342797) | National Cancer Institute (NCI) | 1993-11-17 |
| Multicenter Selective Lymphadenectomy Trial (MSLT) (NCT00275496) | Saint John's Cancer Institute | 1993-11-01 |
| Collecting Tumor Samples From Patients With Gynecological Tumors (NCT00897442) | Gynecologic Oncology Group | 1992-06-01 |
| A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma (NCT00001296) | National Cancer Institute (NCI) | 1992-02-01 |
| Trial of Surgical Excision Margins in Thick Primary Melanoma (NCT01183936) | Karolinska Institutet | 1992-01-01 |
| Trial of Surgical Excision Margins in Thick Primary Melanoma - 2 (NCT03638492) | Peter Gillgren | 1992-01-01 |
| Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma (NCT00588198) | Memorial Sloan Kettering Cancer Center | 1991-10-01 |
| Intraoperative Mapping of Regional Lymphatics Draining the Primary Site of Melanoma Using Isosulfan Blue (NCT00581698) | Memorial Sloan Kettering Cancer Center | 1991-01-01 |
| The French E3N Prospective Cohort Study (NCT03285230) | Institut National de la Santé Et de la Recherche Médicale, France | 1990-06-15 |
| Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma (NCT02416232) | GlaxoSmithKline | |
| TNFerade™ Biologic Plus Radiation for Metastatic Melanoma (NCT00261404) | GenVec | |
| Study of Talabostat and Cisplatin in Advanced Melanoma (NCT00083252) | Point Therapeutics | |
| A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma (NCT00733798) | TransMolecular | |
| Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients (NCT00306514) | Cytos Biotechnology AG | |
| Thalidomide and Dacarbazine for Metastatic Melanoma (NCT00006200) | National Center for Research Resources (NCRR) | |
| Study of Talabostat in Advanced Melanoma (NCT00083239) | Point Therapeutics | |
| Individual Patient Compassionate Use of GX-I7 (NCT04289155) | Genexine, Inc. | |
| Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma (NCT04489433) | Novartis Pharmaceuticals | |
| Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval (NCT06751524) | Agenus Inc. | |
| The Use of Mole Mapping Diagrams to Increase Skin Self Examination Accuracy (NCT00237965) | Brown University | |
| Compassionate Use Trial for Unresectable Melanoma With Ipilimumab (NCT00495066) | Bristol-Myers Squibb | |
| Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection (NCT04544202) | Novartis Pharmaceuticals | |
| Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401 (NCT03593499) | Biogen | |
| SPECTAmel: Screening Patients With Melanoma Tumors for Efficient Clinical Trial Access (NCT02507947) | European Organisation for Research and Treatment of Cancer - EORTC | |